Introduction {#s1}
============

Osteosarcoma is the most common primary bone tumor characterized by the production of osteoid matrix from malignant cells. It typically occurs in the long bones of the near metaphyseal growth plates of children and young adolescents [@pone.0087215-Beckingsale1]. The earliest known case affected a male Celt (ca. 800--600 BC) from Switzerland with a possible osteosarcoma or chondrosarcoma [@pone.0087215-Brothwell1]. A possible osteosarcoma of the pelvis has been noted in a young individual from Ancient Egypt, dating to about 250 AD [@pone.0087215-Ruffer1], and a well-documented case of osteosarcoma, with the typical radiographic "sunburst" pattern, has been reported in the femur of a native Peruvian dating to 800 BP [@pone.0087215-Aufderheide1]. Additional cases of osteosarcoma have been observed in a young female femur from the prehistoric population of Oahu in Hawaii [@pone.0087215-Suzuki1], and in a zygomatic bone from the French Middle Ages [@pone.0087215-Dastugue1] in a case of 17th century mandible from West Virginia [@pone.0087215-Kelln1]. Possible osteosarcomas have been detected in a young male from the Saxon necropolis of Standlake, England [@pone.0087215-Brothwell2] and in medieval skulls from the Czech Republic [@pone.0087215-Strouhal1] and France [@pone.0087215-Blondiaux1]. Probable cranial hemangiosarcoma has been documented in an elderly female from Italy, 3rd Century BC [@pone.0087215-Capasso1] and in a humerus from Peru, 12--14th Centuries AD [@pone.0087215-Aufderheide1] and a possible Ewing\'s sarcoma in a juvenile skull from Bronze Age of Tartaren, Spain [@pone.0087215-Campillo1]. Only a few cases of neoplasms have been documented in Central and South American mummies, for example a rhabdomyosarcoma (4--7th Centuries AD) in 2 children from Chile [@pone.0087215-Gerszten1].

Diagnosis of cancer as well as osteogenic sarcomas from ancient human skeletal remains is not an easy task by using classic morphological methods. Therefore a biomolecular approach to diagnosis in addition to osteological examination can be beneficial [@pone.0087215-Schultz1]. Recently, proteomic profiling of human tumors has provided a better understanding of the molecular pathogenesis of neoplastic diseases and has identified novel biomarkers for early diagnosis. SELDI-TOF-MS (Surface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry) and protein microarray high throughput analysis enable to detect biomarkers from the serum samples of osteosarcoma patients [@pone.0087215-Li1]. Based on the MALDI-TOF analyses of clinical benign and osteosarcomas several biomarkers are up- or down-regulated [@pone.0087215-Li2]. Also MALDI-TOF analysis of human osteosarcoma MG-63 cells showed the alterations of some genes and proteins [@pone.0087215-Zhao1].

Additionally, mass spectrometry (MS) based proteomic studies of paleopathological remains have made sequence information available from subpicomolar quantities of fragmented proteins and peptides [@pone.0087215-Asara1]--[@pone.0087215-Orlando1].

In this study, ancient proteins such as malignant bone tumor related molecular biomarkers were successfully extracted and detected from archaeological human skeletal remains by matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry (MALDI TOF/TOF MS) for the first time. Our proteomic results can enhance the diagnosis of osteogenic tumors in ancient human skeletal remains.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

### Specimen numbers {#s2a1}

Savaria, Szent Marton str. 53/grave 186 (osteosarcoma) and grave 199 (healthy control).

### Repository information {#s2a2}

Savaria Museum, Archaeological Collection, Kisfaludy str. 9, H-9700 Szombathely, Hungary. Department of Anthropology, University of Szeged, Kozepfasor 52, H-6726, Szeged, Hungary.

All necessary permits were obtained for the described study, which complied with all relevant regulations (National Office of Cultural Heritage permission number: 3495/2001).

Archaeological Bone Sample {#s2b}
--------------------------

The fragmented skeleton of a 25--35-year-old female has been excavated at the Late Roman archaeological site of Szombathely (Savaria) - Szent Marton street 53, Hungary (municipal location code 6583/1) grave 186 ([Figure 1](#pone-0087215-g001){ref-type="fig"}). The analyzed bone sample was collected from the cortical region of the right humerus ([Figure 2](#pone-0087215-g002){ref-type="fig"}). The anthropological and paleopathological investigations were carried out based on Knussmann [@pone.0087215-Knussmann1] and Jozsa [@pone.0087215-Jozsa1]. A humerus from a non-cancerous skeletal remain from this cemetery (grave 199, adult female) was used for the investigations as a control sample. For further validation we used our previous proteomic results of some non-pathological and *M. tuberculosis* infected bone samples ([Table 1](#pone-0087215-t001){ref-type="table"} and [2](#pone-0087215-t002){ref-type="table"}).

![The line drawing map of the archaeological site.\
At this site we uncovered 33 graves from the late Roman period, arranged in four rows, very close to each other. Grave 186 (indicated with an red arrow) is located in the south-eastern section of the site, at 270--90°. The upper perimeter dimensions of the grave were 218 by 126 cm, the base 185 by 120 cm, with a depth of 48 cm.](pone.0087215.g001){#pone-0087215-g001}

![The paleoanthropological sample chosen for mass spectrometric analysis.\
A) and B) Anterior and posterior views of the analyzed right humerus with osteogenic sarcoma. C) X-ray radiograph of the measured human remain. The red ellipse shows the location of the sampling.](pone.0087215.g002){#pone-0087215-g002}

10.1371/journal.pone.0087215.t001

###### The analyzed healthy control bone samples.

![](pone.0087215.t001){#pone-0087215-t001-1}

  Location                     Grave     Age      Sex             Period
  --------------------------- ------- --------- -------- ------------------------
  Mohacs                        \-      Adult     Male      Recent (forensic)
  Bataszek                      \-      Adult     Male      Recent (forensic)
  Bataszek                      \-     Senium     Male      Recent (forensic)
  Mohacs                        \-      Adult    Female     Recent (forensic)
  Pecs                          \-      Adult    Female     Recent (forensic)
  Hodmezovasarhely-Gorzsa       16     Senium    Female         Neolithic
  Mezokovesd Patakrajaro        4/a    Adultus    Male         Chalcolithic
  Kiskundorozsma                15     Adultus   Female         Bronze Age
  Algyo Barakktabor              4     Maturus    Male           Scythian
  Szegvar Oromdulo              918    Adultus   Female         Sarmatian
  Kishomok                      89     Maturus   Female           Gepids
  Szegvar Oromdulo              740    Adultus   Female         Early Avar
  Szekkutas Kapolnadulo         30     Adultus   Female         Late Avar
  Kiskundorozsma                100    Senium     Male      Hungarian Conquest
  Esztergalyhorvath             284    Adultus   Female     Hungarian Conquest
  Kecskemet Torokfaj            65     Maturus   Female   Arpad Age, X-XI^th^ AD
  Szegvar Oromdulo              617    Maturus   Female    Arpad Age, XI^th^ AD
  Derekegyhaza Ibolyas          13     Senium     Male        XI-XII^th^ AD
  Csengele Bogarhat             57     Adultus    Male         XIII^th^ AD
  Kecskemet Ferences church     350    Adultus   Female       XIV-XV^th^ AD

10.1371/journal.pone.0087215.t002

###### The measured pathological control (*Mycobacterium tuberculosis* infected) archaeological bone samples.

![](pone.0087215.t002){#pone-0087215-t002-2}

  Location                  Grave     Age      Sex         Period
  ------------------------ ------- --------- -------- -----------------
  Sukosd-Sagod               19      Adult    Female   VII-VIII^th^ AD
  Sukosd-Sagod               19      Adult    Female   VII-VIII^th^ AD
  Bacsalmas-Homokbanya       39     Maturus    Male      XVII^th^ AD
  Bacsalmas-Homokbanya       39     Maturus    Male      XVII^th^ AD
  Belmegyer-Csomoki hill     65     Maturus   Female     VIII^th^ AD
  Belmegyer-Csomoki hill     65     Maturus   Female     VIII^th^ AD
  Csongrad-Elles             183    Maturus    Male    XI-XIII^th^ AD
  Csongrad-Elles             183    Maturus    Male    XI-XIII^th^ AD
  Csongrad-Elles             183    Maturus    Male    XI-XIII^th^ AD
  Csongrad-Elles             183    Maturus    Male    XI-XIII^th^ AD
  Csongrad-Felgyo            205     Adult    Female     VIII^th^ AD
  Csongrad-Felgyo            205     Adult    Female     VIII^th^ AD

Extraction of Ancient Proteins {#s2c}
------------------------------

The sample preparation, separation and mass spectrometric analysis is of a vital importance for the quality of the results. In our previous study we developed an optimized workflow for proteomic analysis of ancient proteins [@pone.0087215-BorosMajor1]. Here, we used this method with some modifications. Briefly, the bone fragments were washed to remove contaminants with phosphate buffer saline (PBS) and distillated water. Bone powder was ground by hand with an agate mortar, the particle size was ∼0.2 mm. Next, 100 mg of crude bone powder was decalcified with 1.00 ml of 0.5 M EDTA (pH = 8.0), the pellet was resuspended with 100 µl of 6 M guanidine-HCl in 0.1 M Tris (pH = 7.5) at room temperature. The extraction of the proteins was carried out by continuous shaking at 4°C for 8 hours with the presence of protease inhibitor cocktail (Sigma Aldrich Kft., Budapest, Hungary). The protein extract was purified by using C~18~ solid phase extraction (SPE) cartridge. For this purification step a homemade octadecylsilane modified silica-based stationary phase was used with average particle size of 5 µm and pore size of 120 Å. The stationary phase was activated with an aqueous 0.1% TFA solution, the loaded protein extract was washed with 100 µl of 2% acetonitrile in 0.1% TFA three times, then the proteins were eluted by 50 µl of 50% acetonitrile in 0.1% TFA solution. The solution was lyophilized to powder and stored at −86°C until further processing.

The bone sample with tumorous lesion was measured in eight technical replicates.

SDS-PAGE Gel Electrophoresis and Enzymatic Digestion {#s2d}
----------------------------------------------------

100 µL of protein extract of the archaeological sample in 20 mM Tris/HCl buffer, pH 7.4 containing 3 mM EDTA, 5 mM betamercaptoethanol and 1% sodium dodecylsulfate (SDS) was homogenized by using Ultra Turrax homogenizer. After the addition of 1% bromphenolblue, the samples were boiled for 2 minutes and clarified by centrifuging (8000 g for 2 min). Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out on 12% gel by Laemmli\'s method. A low molecular weight calibration kit (Pharmacia) was used for estimation of the molecular weight. To increase the quality of the separation and visibility of the spots the gel was run at 4°C. Gels were stained with Coomassie brillant blue R-250 and destained with a solution containing 5% (v/v) acetic acid and 16% (v/v) methanol.

The spots of the overexpressed proteins (compared to the healthy archaeological samples) were excised from the gel with a razorblade, placed in Eppendorf tubes, and destained by washing three times for 10 min in 200 µL of 50% (v/v) acetonitrile solution containing 50 mM NH~4~HCO~3~. Proteins were then reduced by 50 µL of 20 mM dithiotreitol, 100 mM NH~4~HCO~3~ and acetonitrile 5% for 1 h at 55°C and alkylated in 50 µL of 20 mM iodoacetamide solution. The gel pieces were dehydrated at room temperature by a Speed Vac Concentrator (Speed Vac Plus, SC100A, Savant) and covered with 10 µL of modified trypsin (Promega, Madison, WI, sequencing grade) (0.04 mg×mL^−1^) in Tris buffer (2.5 mM, pH 8.5) and left at 37°C overnight. The excised spots were crushed and peptides were extracted in an ultrasonic bath (15 min) with 15 µL aqueous solution of acetonitrile and formic acid (49/50/1 v/v/v).

MALDI TOF/TOF Mass Spectrometry-based Identification of the Ancient Proteins {#s2e}
----------------------------------------------------------------------------

After extraction the peptide solutions were lyophilized and redissolved in 0.1% trifluoroacetic acid (TFA). The aqueous solutions of the lyophilized protein digests were concentrated and desalted by using C~18~ ZipTip SPE pipette tips (Millipore Kft, Budapest, Hungary) then the purified peptides were eluted directly onto the target plate (MTP 384 massive target T, Bruker Daltonics, Bremen, Germany) by using of 3 µL of a saturated matrix solution, prepared fresh every day by dissolving α-cyano-4-hydroxycinnamic acid (CHCA) in acetonitrile/0.1% TFA (1/2, v/v). The mass spectrometer used in this work was an Autoflex II TOF/TOF (Bruker Daltonics, Bremen, Germany) operated in reflectron mode for peptide mass fingerprinting (PMF) or LIFT mode for LID (laser induced decay) and CID (collision induced decay). The FlexControl 2.4 software was used to control the instrument. The accelerating voltage was set to 20.00 kV. The instrument uses a 337 nm nitrogen laser (model MNL-205MC, Lasertechnik Berlin GmbH., Berlin, Germany). External calibration was performed in each case using Bruker Peptide Calibration Standard (\#206195 Peptide Calibration Standard, Bruker Daltonics, Bremen, Germany). Peptide masses were acquired in the range of m/z 700 to m/z 5000. Each spectrum was produced by accumulating data from 1000 consecutive laser shots. Singly charged monoisotopic peptide masses were searched against Swiss-Prot and NCBI nr databases (last accessed: 11/19/2012) by utilizing the MASCOT database search engine (version 2.2) ([www.matrixscience.com](http://www.matrixscience.com), Matrix Science Ltd., London, UK) and Bruker ProteinScape server 2.1 (Bruker Daltonics, Bremen, Germany). Maximum one missed tryptic cleavage was considered, and the mass tolerance for monoisotopic peptide masses was set to 80 ppm. Carbamidomethylation was set as global modification while methionine oxidation was set as variable modification. Additionally LID and CID fragmentation of the matched peptides were carried out for MALDI TOF/TOF to provide further evidence for the presence of the identified proteins.

Statistical Analysis {#s2f}
--------------------

To demonstrate the predictive value of the identified biomarkers the mass spectrometric results were statistically evaluated by ClinProTools 2.2 (Bruker Daltonics, Bremen, Germany) clustering software. Multiple spectra of the analyzed bone samples from different sample cohorts, such as osteosarcoma, non-pathological and pathological (tuberculotic) control samples were distinguished together. Recalibration, spectral alignment, peak normalization, peak detection and peak area calculation of spectra were carried out automatically by ClinProTools. A logistic regression model was performed to identify the significant predictive peaks on the basis of the normalized peak areas. Wilcoxon signed-rank test was used for non-parametric statistical analysis of the different sample cohorts.

Results and Discussion {#s3}
======================

This work focused on the identification of possible protein biomarkers of osteogenic sarcoma from a 2000-year-old anthropological sample. The proteins were separated by 1D gel electrophoresis and the interested spots were enzymatically digested ([Figure 3](#pone-0087215-g003){ref-type="fig"}). The tryptic peptides were analyzed by MALDI TOF/TOF MS and the identification of the resulted proteins was carried out using a PMF or MS/MS search. Based on our results several known, previously published osteosarcoma or tumor related proteins and gene products were detected from the ancient pathological bone sample ([Table 3](#pone-0087215-t003){ref-type="table"}).

![Characteristic 1D SDS PAGE electrophoretogram of healthy control and the pathological bone samples.\
Lanes 1 and 2 are healthy control samples from Hodmezovasarhely-Gorzsa and Szegvar-Oromdulo, lanes 3--6 are osteosarcoma samples. Arrows show the spots of Annexin A10 (37.3 kDa) and Vimentin (26.8 kDa). The parameters of the separation are mentioned in the text.](pone.0087215.g003){#pone-0087215-g003}

10.1371/journal.pone.0087215.t003

###### The identified up-regulated proteins from 2000-year-old osteogenic sarcoma.

![](pone.0087215.t003){#pone-0087215-t003-3}

  Accession                                   Name                               MW \[kDa\]   Peptides   SC \[%\]
  -------------- -------------------------------------------------------------- ------------ ---------- ----------
  AK1A1_HUMAN                    Alcohol dehydrogenase (NADP+)                      36,5         5         14,2
  gi\|225939                           aldehyde reductase                           36,3         5         14,2
  gi\|48762937                            annexin A10                               37,3         8         27,2
  gi\|62087532           arginine/serine-rich splicing factor 6 variant             31,8         6         27,6
  ARI5B_HUMAN           AT-rich interactive domain-containing protein 5B           132,2         11        13,0
  gi\|33878074                            BAT2 protein                              17,1         5         29,9
  gi\|49456879                               BCL2A1                                 20,3         7         44,0
  VMDL3_HUMAN                             Bestrophin-4                              76,1         7         14,5
  gi\|882391               bone morphogenic protein type II receptor                59,9         6         13,2
  S10AB_HUMAN            Calgizzarin (S100 calcium-binding protein A11)             11,7         4         43,8
  CAN7_HUMAN                               Calpain-7                                92,6         7         12,3
  K1C10_HUMAN                            Cytokeratin 10                             59,5         14        23,1
  gi\|33188433                deleted in liver cancer 1 isoform 1                  170,5         13        7,9
  gi\|28704113                            DHX8 protein                             138,7         13        13,8
  G59435                                     DLC-1                                 122,7         10        10,9
  DNL3_HUMAN                             DNA ligase III                            102,6         10        16,3
  TDT_HUMAN                      DNA nucleotidylexotransferase                      58,4         9         22,2
  MP2K6_HUMAN      Dual specificity mitogen-activated protein kinase kinase 6       37,5         7         23,4
  DTNA_HUMAN                           Dystrobrevin alpha                           83,9         6         10,5
  gi\|15010856                       galectin-12 isoform d                          30,0         5         30,5
  GCC2_HUMAN            GRIP and coiled-coil domain-containing protein 2           184,5         18        12,3
  gi\|40555827               heat shock factor protein 2 isoform c                  27,0         7         23,9
  HSPB6_HUMAN                      Heat-shock protein beta-6                        17,1         5         35,0
  CAC10772                 Immunoglobulin heavy chain variable region               12,4         5         65,5
  gi\|17318569                             keratin 1                                66,0         15        25,8
  Q8N175_HUMAN                             Keratin 10                               58,8         14        23,5
  gi\|31559819                            keratin 25C                               49,8         8         17,2
  gi\|47132620                             keratin 2a                               65,4         9         16,4
  CAA82315                                 keratin 9                                62,1         11        16,9
  A44861                         keratin, 67K type II epidermal                     65,8         9         16,3
  K1C9_HUMAN                     Keratin, type I cytoskeletal 9                     61,9         11        20,7
  AAP97338                    Methyl-CpG-binding domain protein 4                   60,9         13        16,3
  NEBL_HUMAN                               Nebulette                               116,4         14        16,7
  NRAP_HUMAN                   Nebulin-related-anchoring protein                   197,0         24        14,9
  gi\|4506335                             parvalbumin                               12,1         8         56,4
  PRVA_HUMAN                           Parvalbumin alpha                            11,9         8         56,9
  gi\|39653323               PHD finger protein 20-like 1 isoform 1                 47,7         7         15,8
  gi\|39653321               PHD finger protein 20-like 1 isoform 3                 16,6         6         42,0
  gi\|31873386                          phospholipase C                             39,7         7         30,7
  gi\|346323       phosphoprotein phosphatase (EC 3.1.3.16) X catalytic chain       35,1         6         26,1
  PDIP2_HUMAN                Polymerase delta-interacting protein 2                 42,0         7         22,0
  CAF00150                       Proteasome subunit beta type 3                     16,6         5         34,9
  gi\|565647                      proteasome subunit HsC10-II                       22,9         5         25,4
  PARK7_HUMAN                     Protein DJ-1 (Oncogene DJ1)                       19,9         5         32,3
  gi\|55859594                           PTAR1 protein                              32,4         7         30,1
  gi\|4960030                 Rab GDP dissociation inhibitor beta                   41,0         6         22,0
  gi\|39841018                RAB GTPase activating protein 1-like                  92,5         8         10,3
  gi\|537327                        receptor tyrosine kinase                        18,5         6         30,0
  gi\|2665850                       rheumatoid factor RF-ET7                        10,9         6         74,5
  RHG07_HUMAN                   Rho GTPase-activating protein 7                    122,7         10        10,9
  gi\|41152086    serine (or cysteine) proteinase inhibitor, clade B, member 6      42,6         9         29,3
  gi\|38382764                   SET-binding protein isoform b                      26,4         7         25,6
  gi\|46250431                      Transcription factor NRF                        77,7         11        20,4
  gi\|62088924    Transducin-like enhancer of split 3 splice variant 1 variant      22,9         6         37,1
  gi\|37747855                            Transferrin                               77,0         10        21,9
  gi\|4507659       translocated promoter region (to activated MET oncogene)       265,4         24        12,0
  gi\|4827050                    ubiquitin specific protease 14                     56,0         8         20,6
  gi\|71774197                   ubiquitin specific protease 47                    147,1         10        13,4
  gi\|34532272       unnamed protein product (homolog of CCDC144A protein)          56,3         12        21,9
  gi\|21754902    unnamed protein product (homolog of Zinc finger protein 781)      17,8         7         48,7
  gi\|57471648                              vimentin                                26,8         8         38,2
  WBP4_HUMAN                      WW domain-binding protein 4                       42,5         7         15,7
  ZN224_HUMAN                       Zinc finger protein 224                         82,2         10        19,4
  gi\|74355161                      Zinc finger protein 624                         85,6         11        22,5

(Mascot score\>50).

The identified annexins (ANXs) are calcium and phospholipid binding proteins, they play a crucial role in the exocytic and endocytic transport, regulation of cell growth, proliferation and apoptosis. It is well known, that the increased level of ANX (ANXA-10) indicates tumor progression [@pone.0087215-Shimizu1], [@pone.0087215-Kim1]. The B-cell lymphoma 2-related protein A1 (BCL2A1) is a member of BCL2 proteins. BCL2A1 is responsible for the separation of pro-apoptotic BCL2 proteins. BCL2A1 shows an elevated level in case of different cancer types such as leukemia and lymphoma, also connected with autoimmunity and therapy resistance of different tumors [@pone.0087215-Bolden1]--[@pone.0087215-Vogler1]. Calgizzarin (S100A11) belongs to the calcium binding proteins S100 family, involved in cell growth, motility and differentiation. Calgizzarin has been correlated with tumor progression and metastasis [@pone.0087215-Melle1], [@pone.0087215-Rehman1]. DLC1 is a known tumor suppressor, acting through Rho GTPase-activating protein (RhoGAP), which is involved in the proliferation and migration of tumor cells, induces apoptosis in vitro [@pone.0087215-Yang1]--[@pone.0087215-Zhang1]. Heat-shock protein\'s (HSP\'s) expression increases in case of thermal, physiological or other stress factors allowing the cells to survive lethal conditions. HSP\'s play key role in the apoptotic and cell death process (inhibition of caspase activation). Elevated level of HSP beta-6 was found in clinical samples of patients who suffered from osteosarcoma [@pone.0087215-Suehara1], [@pone.0087215-Folio1]. DJ-1 protein is a mitogen-dependent oncogene involved in ras-related signal transduction pathway. Overexpression of DJ-1 indicates tumorous mutation [@pone.0087215-Tian1], [@pone.0087215-Niforou1]. The RhoGAP family proteins play an important role in regulating cell migration, cell morphology and cytoskeletal organization. Down regulation of RhoGAP proteins decrease the tumor suppressive effect [@pone.0087215-Li3]. Transferrin is a member of iron-binding blood plasma glycoproteins, that is responsible for the regulation of the free iron content in the blood. Elevated level of transferrin is correlated with tumorous diseases such as osteosarcoma [@pone.0087215-Suehara1], [@pone.0087215-Li4]. The expression of a cytoskeletal intermediate filament protein vimentin (VIM) was also shown to increase in case of osteosarcoma [@pone.0087215-Suehara1], [@pone.0087215-Li4]--[@pone.0087215-Kang1]. VIM is considered to be a tumor biomarker, as it is promoting the metastatic spread of the tumor cells. In this study, some keratins were identified as well. The origin and the importance of these proteins are not well known, probably the identified keratins are from recent or contemporary contaminations. However, the up-regulation of cytokeratins has been published in U2OS osteosarcoma specific cell line [@pone.0087215-Niforou1].

Representative mass spectra and the list of the identified tryptic peptides of annexin A10 and vimentin are showed on [Figure 4](#pone-0087215-g004){ref-type="fig"}. The results show characteristic peaks of the identified biomarkers, however some keratin peaks are present on the spectra. This pollution is common from ancient bone tissue, but various types of keratins are up-regulated in different tumors as well.

![Representative mass spectra and the list of the identified tryptic peptides of two identified tumor biomarkers.\
A) Annexin A10, B) Vimentin. Some keratin contamination has been detected in the sample, the tryptic peptides of keratin were used as internal calibration standards and the peaks are marked with asterisk.](pone.0087215.g004){#pone-0087215-g004}

Based on our statistical analysis the different sample cohorts such as osteosarcoma, healthy control and tuberculotic control could be distinguished, therefore the spectral profile of the samples with osteosarcoma is significantly different as the other two group\'s profiles ([Figure 5](#pone-0087215-g005){ref-type="fig"}). The predictive peaks are showed in [Table S1](#pone.0087215.s001){ref-type="supplementary-material"}, where the statistical parameters are given for the most predictive molecular masses.

![ClinProTools-based Wilcoxon non-parametric statistical test of different sample cohorts.\
Cluster analysis from sample sets of the osteosarcoma (green), healthy control sample (red) and tuberculotic control sample (blue) groups using the peptide peaks with m/z 1180 and 1385. The x-and y-axes correspond to the relative intensities of the peptide peaks.](pone.0087215.g005){#pone-0087215-g005}

Conclusions {#s4}
===========

The aim of our study was to find potential tumor biomarkers for ancient osteosarcoma using healthy bone samples as a control. Certain proteins, which are characteristic for tumorous disease can be extracted from the diseased cells, were presumably transported earlier by the blood and absorbed to the bone hydroxyapatite [@pone.0087215-Schultz2]. Using an appropriate extraction method, developed by our research group, followed by SDS PAGE, tryptic digestion and MALDI TOF/TOF, we were able to identify several proteins that were tightly connected to tumorous mutations. The overexpression of annexin A10 protein, BCL-2-like protein, calgizzarin, HSP beta-6, RhoGAP-activating protein 7, transferrin, and vimentin among others referred to healthy samples may indicate the presence of tumor in bones. In this study, we demonstrated that the peptide profile of the samples with osteosarcoma is statistically unique and it could be distinguished from other sample cohorts.

On the basis of our results the proteomic analyses could indicate the presence of osteosarcoma in bone tissues. Our findings showed that the well known, osteosarcoma-related clinical protein biomarkers are detectable in the investigated 2000-year-old tumorous skeletal remain. In the future, additional comparative proteomic investigations are needed for further early stage biomarker discovery of ancient primary bone cancer.

Supporting Information {#s5}
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The statistical parameters of the mass spectrometric results.
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Click here for additional data file.
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